Headline »
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease
Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Aim to Cure, Analysis, Featured, Headline, Industry News

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain

Submitted by Robert Lawrence on Wednesday, 24 June 2009No Comment

Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription only in 50-mg, 75-mg and 100-mg tablets, announced PriCara,(R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.